Security Snapshot

Traws Pharma, Inc. - Common Stock, par value $0.01 per share (TRAW) Institutional Ownership

CUSIP: 68232V884

13F Institutional Holders and Ownership History from Q3 2024 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

26

Shares (Excl. Options)

3,619,791

Price

$1.83

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Type / Class
Equity / Common Stock, par value $0.01 per share
Symbol
TRAW on Nasdaq
Shares outstanding
16,062,541
Price per share
$1.16
All holders as of 31 Mar 2026
Q1 2026
Total 13F shares
3,619,791
Total reported value
$6,624,221
% of total 13F portfolios
0%
Share change
+201,203
Value change
+$459,630
Number of holders
26
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Key facts

  • TRAW - Traws Pharma, Inc. - Common Stock, par value $0.01 per share is tracked under CUSIP 68232V884.
  • 26 institutions reported positions in Q1 2026.
  • 8 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 21 to 26 between Q4 2025 and Q1 2026.
  • Reported value moved from $3,863,003 to $6,624,221.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 26 institutions filings for Q1 2026.

Open SEC Evidence

Security key

68232V884

Latest holder period

Q1 2026

13F holders

26

13D/G owners

8

CIK / CUSIP context first

Open Q1 2026 holders TRAW full holder history Traws Pharma, Inc. SEC filings Traws Pharma, Inc. company facts Traws Pharma, Inc. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

Significant Owners of Traws Pharma, Inc. - Common Stock, par value $0.01 per share (TRAW) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ORBIMED ADVISORS LLC 12% -40% $3,431,754 +$2,040,131 1,876,198 +147% ORBIMED ADVISORS LLC 16 Apr 2026
PERCEPTIVE ADVISORS LLC 6.1% -39% $1,793,061 +$170,058 979,815 +10% Perceptive Advisors LLC 31 Mar 2026
Ikarian Capital, LLC 10% 0% $1,308,164 +$359,065 812,524 +38% Ikarian Capital, LLC 31 Dec 2025
Adage Capital Management, L.P. 9.1% +89% $1,175,300 +$644,000 730,000 +121% Adage Capital Management, L.P. 31 Dec 2025
Chernett Jorey 6.8% $668,220 543,268 Chernett Jorey 14 Jan 2026
Squadron Capital Management LLC 6.4% -28% $936,437 -$369,342 511,714 -28% Squadron Master Fund LP 31 Mar 2026
Ayrton Capital LLC 4.3% -56% $552,125 -$97,751 342,935 -15% Ayrton Capital LLC 31 Dec 2025
Alyeska Investment Group, L.P. 9.9% $462,446 302,252 Alyeska Investment Group, L.P. 31 Dec 2024

As of 31 Mar 2026, 26 institutional investors reported holding 3,619,791 shares of Traws Pharma, Inc. - Common Stock, par value $0.01 per share (TRAW). This represents 23% of the company’s total 16,062,541 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Traws Pharma, Inc. - Common Stock, par value $0.01 per share (TRAW) together control 23% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
ADAGE CAPITAL PARTNERS GP, L.L.C. 4.5% 730,000 0% 0% $1,335,900
Ikarian Capital, LLC 4.2% 678,142 0% 0.18% $1,241,000
ORBIMED ADVISORS LLC 3.8% 605,531 0% 0.03% $1,108,122
Squadron Capital Management LLC 3.2% 511,714 -28% 0.37% $936,437
Dauntless Investment Group, LLC 2.6% 416,998 2.1% $763,106
BOOTHBAY FUND MANAGEMENT, LLC 1.2% 194,536 0% 0.01% $356,001
ADAR1 Capital Management, LLC 0.96% 154,098 -0.22% 0.02% $281,999
GEODE CAPITAL MANAGEMENT, LLC 0.48% 77,103 +25% 0% $141,100
Palumbo Wealth Management LLC 0.38% 61,175 0.03% $111,951
VANGUARD CAPITAL MANAGEMENT LLC 0.34% 55,193 0% 0% $101,003
VANGUARD FIDUCIARY TRUST CO 0.2% 31,804 0% 0% $58,201
STATE STREET CORP 0.16% 25,802 0% 0% $47,218
JANE STREET GROUP, LLC 0.13% 21,241 0% $38,871
TWO SIGMA INVESTMENTS, LP 0.12% 19,244 0% 0% $35,217
Lynx1 Capital Management LP 0.09% 15,078 0% $27,593
BlackRock, Inc. 0.06% 9,956 0% 0% $18,219
UBS Group AG 0.03% 4,053 -48% 0% $7,417
Tower Research Capital LLC (TRC) 0.02% 3,964 0% $7,254
MORGAN STANLEY 0.02% 3,729 0% $6,824
Vanguard Global Advisers, LLC 0% 262 0% 0% $479
SBI Securities Co., Ltd. 0% 128 -21% 0% $234
FMR LLC 0% 23 +1050% 0% $42
Cassaday & Co Wealth Management LLC 0% 11 0% $21
JONES FINANCIAL COMPANIES LLLP 0% 2 0% $4
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO 0% 2 0% $4

Institutional Holders of Traws Pharma, Inc. - Common Stock, par value $0.01 per share (TRAW) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 3,619,791 $6,624,221 +$459,630 $1.83 26
2025 Q4 3,418,588 $3,863,003 +$1,409,923 $1.13 21
2025 Q3 1,304,595 $2,413,244 +$101,966 $1.85 18
2025 Q2 1,263,487 $1,869,962 -$1,075,287 $1.48 19
2025 Q1 1,732,309 $3,984,315 +$1,207,345 $2.30 18
2024 Q4 1,141,975 $10,140,752 +$4,400,867 $8.88 17
2024 Q3 646,356 $3,800,574 +$3,742,033 $5.88 10
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .